Home » Newsletters » BioWorld Science

BioWorld Science

April 3, 2020

View Archived Issues

Females, males have different metabolic response to intermittent fasting

First patient dosed in phase I/IIa study of TJC-4 in China

Positive data from investigator-initiated trial of DAS-181 for the treatment of COVID-19

Topline phase Ib/IIa results for AB-2004 in patients with ASD

Update on phase II study of ifenprodil in patients with COVID-19

Leronlimab shows potential immunological restoration in severely ill COVID-19 patients

Novel bleomycin-induced cynomolgus monkey model of IPF

Serum indoxyl sulfate as independent biomarker of arterial stiffness in CAD

Serum EV-Tspan8 level predicts distant metastasis in NSCLC

Silverback Therapeutics discloses new benzazepine compounds

ERN1 inhibitors discovered at Genentech

British American Tobacco announces work on potential vaccine for COVID-19

Roche identifies antagonists of Toll-like receptors

Crinetics Pharmaceuticals presents somatostatin SST2 receptor agonists

Terns synthesizes new ABL1/ABL2/Bcr-Abl inhibitors

Researchers develop a mouse model of 3q.29 deletion-driven psychiatric disorder

GigaGen developing recombinant polyclonal antibody therapy rCIG for COVID-19

New protein tau tracer [18F]THK-5562 developed for diagnosing Alzheimer's disease

X, Y copies of neuroligin-4 have different functions

Incyte and Novartis plan phase III evaluation of Jakavi for COVID-19-associated cytokine storm

Researchers create rat model of AKI to CKD progression

Vanda begins phase III study of tradipitant in hospitalized patients with COVID-19 pneumonia

FDA clears IND for phase I/II study of NK cell therapy CYNK-001 for COVID-19

European Commission approves rituximab biosimilar Ruxience

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Cosmo data positive for first new hair-loss approach in decades
BioWorld
Shares of Cosmo Pharmaceuticals NV rose sharply on Dec. 3 following top-line pivotal phase III data showing a statistically significant and clinically meaningful...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...